Clinical Trial Update: Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma [Phase 2]

View source ↗

Summary

Phase 2 results from a trial investigating the 24-hour FEV1 profile after a single dose of indacaterol/mometasone delivered via the TWISTHALER in adults with pe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Indacaterol/Mometasone (TWISTHALER)

Snippet

Sponsor: Novartis | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2013-03-21